First Warning Systems Receives Investment by Members of the Reno Angels and Local Investors

RENO, Nev., Aug. 6, 2012 /PRNewswire/ -- First Warning Systems, Inc. announces members of the Reno Angels have joined together with local investors to invest in the First Warning Systems $1,000,000 Series A funding round. 

Jim Holmes, First Warning's CEO states, "We are approaching fifty percent completion of this Series A round of financing.  We appreciate members of the Reno Angels and local investors' support of the First Warning System." 

For particulars concerning the Series A round, please check First Warning's website: www.firstwarningsystems.com/series-a-funding.html.

The First Warning patented technology uses predictive analytics software to penetrate imaging technology barriers that are limited to viewing a tumor that, on average, has been growing for 11 years.  Deep tissue temperature analysis from 12 hours of dynamic data collection is modeled using predictive analytics software to compare circadian body rhythms that can identify abnormalities up to 6 years prior to imaging technologies. The First Warning product vision video can be seen at www.firstwarningsystems.com

Holmes adds, "We are planning the establishment of a production facility for our products, determining employee requirements to support worldwide marketing and sales.  We are investigating and hopeful of being able to establish these operations in the Truckee Meadows area."        

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, is based in Reno, NV.  FWS' principal shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO). FWS holds the exclusive worldwide license from Lifeline Biotechnologies for development, manufacturing and marketing of the software-based technologies. The FWS product line is a patented device and process that detects breast tissue abnormalities for health risk assessment and management earlier than any other known modalities.  These tissue abnormalities can lead to breast cancers. Three clinical trials with over 650 participants have achieved proof of concept and superior outcomes with industry leading 90% accuracy.  FWS is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the FWS predictive analytics product.  FWS is preparing for Euro CE Mark and marketing in the UK, EU and Russian markets.  For more information check www.firstwarningsystems.com

For more information, contact: Jim Holmes, CEO 775-324-3822 or 775-852-3222, [email protected] 

SOURCE First Warning Systems, Inc.